180 Life Sciences Corp., a biotechnology company based in Palo Alto, California, has filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (SEC) on April 17, 2024. The filing is intended to register an additional 198,943 shares of the company's common stock under its 2022 Omnibus Incentive Plan, following an amendment that increased the number of shares reserved for issuance. This move comes after the company's previous filings on August 9, 2022, and August 30, 2023. The newly registered shares are designated for employee incentives, aiming to attract and retain talent by offering stock options and restricted stock. The registration incorporates by reference several of the company's previously filed SEC documents, including the Annual Report for the year ended December 31, 2023. The company's Chief Executive Officer, James N. Woody, has signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.

180 Life Sciences Corp., a biotechnology company based in Palo Alto, California, has filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (SEC) on April 17, 2024. The filing is intended to register an additional 198,943 shares of the company's common stock under its 2022 Omnibus Incentive Plan, following an amendment that increased the number of shares reserved for issuance. This move comes after the company's previous filings on August 9, 2022, and August 30, 2023. The newly registered shares are designated for employee incentives, aiming to attract and retain talent by offering stock options and restricted stock. The registration incorporates by reference several of the company's previously filed SEC documents, including the Annual Report for the year ended December 31, 2023. The company's Chief Executive Officer, James N. Woody, has signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.